Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Applied Spectral Imaging and WaveSense have entered into an agreement in which both companies will engage in combined sales and marketing of ASI’s GenASIs imaging and analysis instrument and WaveSense’s EpiSep cell recovery and enrichment solution. The combined solution provides an integrated cell capturing solution and computerized instrument to detect, image, and analyze the captured cells.
Abbott announced CE Marking for its Architect clinical chemistry hemoglobin A1c (HbA1c) test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes.
Crescendo Bioscience announced that the Wadsworth Center at the New York Department of Health, through its Clinical Laboratory Evaluation Program, issued a laboratory permit to Crescendo Bioscience to provide services to physicians in New York. Crescendo offers Vectra DA, a multi-biomarker blood test that measures disease activity in rheumatoid arthritis by integrating 12 key proteins consistently associated with the biology of RA into one objective, quantitative score to help physicians make more informed patient management decisions. Vectra DA is now
Audit MicroControls has added to its line of calibration verification/linearity products, the beta-hydroxybutyric acid linearity, five levels. The control is intended to simulate human patient serum samples for determining linearity, calibration verification, and verification of reportable range for beta-hydroxybutyric acid. Packaged as 5 × 1 mL, this liquid product has a shelf life of two years and an open-vial stability of seven days when stored at 2° to 8°C. Audit MicroControls, 866-252-8348
The FDA has approved Roche Diagnostics’ Tarceva (erlotinib) tablets for the initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have certain epidermal growth factor receptor (EGFR)-activating mutations as detected by an FDA-approved test. The FDA also approved Roche’s Cobas EGFR mutation test. In the United States, Tarceva is already approved, irrespective of histology or biomarker status, for people with advanced-stage NSCLC whose cancer has not spread or grown after initial treatment with certain types of
Boulder Diagnostics has launched in Europe its ParaFlor kits for the detection of Giardia, Cryptosporidium, and Blastocystis infections for human and veterinary applications. The rapid assays enable detection in less than 10 minutes in fresh and fixed stool samples. They are also available for veterinary applications and research use only in humans in the United States. The ParaFlor B kit is the first specific assay for the detection of the Blastocystis parasite. Boulder Diagnostics, 720-897-6276
ScopeLED, a division of Dicon Fiberoptics, has released its LED-based fluorescence microscope illuminator, which is designed to fit most clinical fluorescence microscopes. The ScopeLED F-series illuminators mount directly to the microscope’s fluorescence illuminator and look like a standard microscope lamp house. With more than 30,000 hours of LED lifetime, no maintenance should be required for over 12 to 15 years of heavy lab usage. Power consumption is under 5 W per hour compared to more than 300 W per hour
Siemens Healthcare Diagnostics has obtained FDA clearance for its anti-cyclic citrullinated peptide (anti-CCP) IgG assay to aid diagnosis of rheumatoid arthritis (RA). Available on the company’s Immulite 2000/2000 XPi immunoassay systems, the assay enables laboratories to integrate RA testing onto an automated, random-access analyzer. With a clinical specificity of 97 percent, the Immulite anti-CCP IgG assay is a highly accurate diagnostic tool for fast and early RA diagnosis. The assay helps rule out other inflammatory and arthritic conditions, enabling physicians
TriLink BioTechnologies has signed a licensing agreement with QuantiBact to offer twisted intercalating nucleic acid (TINA) modified oligonucleotides. TINA molecules are intercalators placed at the 5’ end of primers to stabilize duplex formation. Their properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA oligos may find applications wherever an enhanced Tm is required, such as triplex formation or gene silencing. TINA-modified oligonucleotides are now available from TriLink. Visit trilink biotech.com/TINA for up-to-date information. TriLink BioTechnologies, 800-863-6801
Biocare Medical’s uroplakin II mouse monoclonal antibody (IVD) is now available. Studies have shown UP II mRNA to be expressed in bladder cancer tissues and the peripheral blood of patients with primary and metastatic urothelial carcinoma. Pathologists have used uroplakin III [AU1] to establish urothelial origin of the bladder; however, use of UP III is limited owing to its poor sensitivity. UP II was found to have 79 percent (44/56) sensitivity for bladder urothelial carcinoma compared with 34 percent (19/56)
